NCT01049425 - Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer | Biotech Hunter

Enrollment

3,198

Participants

Timeline

Start Date

February 5, 2009

Primary Completion Date

March 1, 2017

Study Completion Date

May 15, 2018

Conditions

Primary Breast CancerHer2 Non-overexpressing

Interventions

DRUG

Epirubicin

4 cycles, intravenous use, day 1 every three weeks

DRUG

Cyclophosphamide

4 cycles, intravenous infusion, day 1 every three weeks

DRUG

Docetaxel

4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy

DRUG

Cyclophosphamide

6 cycles, intravenous infusion, day 1 every 3 weeks

DRUG

Docetaxel

6 cycles, intravenous infusion, day one every three weeks

Trial Locations (1)

Bethesda Krankenhaus, Mönchengladbach